⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952657 | 0.80 | GRM4 (0.61) | — | |
| SCHEMBL29952939 | 0.80 | GRM4 (0.61) | — | |
| SCHEMBL2809553 | 0.80 | GRM4 (0.61) | — | |
| SCHEMBL15057785 | 0.78 | — | — | |
| SCHEMBL5663765 | 0.77 | GRM4 (0.52) | — | |
| SCHEMBL5663760 | 0.77 | GRM4 (0.52) | — | |
| SCHEMBL25492047 | 0.76 | GRM4 (0.58) | — | |
| SCHEMBL25492075 | 0.76 | GRM4 (0.58) | — | |
| SCHEMBL23833793 | 0.76 | GRM4 (0.58) | — | |
| SCHEMBL1063416 | 0.76 | CYP1A2 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220111052-A1 | ELUENT SOLUTION | GE HEALTHCARE LTD (GB) | 2022-04-14 | — | — | US | claimed |
| EP-3766522-B1 | AUTOMATED METHOD FOR THE PREPARATION OF 18F-FLUCICLOVINE COMPOSITIONS | GE HEALTHCARE LTD (GB) | 2022-03-23 | — | — | EP | claimed |
| EP-3766522-A1 | AUTOMATED METHOD FOR THE PREPARATION OF 18F-FLUCICLOVINE COMPOSITIONS | GE Healthcare Limited (GB) | 2021-01-20 | — | — | EP | claimed |
| EP-2793954-B1 | 18F-FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS | GE HEALTHCARE LTD (GB) | 2020-10-21 | — | — | EP | claimed |
| US-20150231249-A1 | 18F-FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS | GE HEALTHCARE LIMITED (GB) | 2015-08-20 | — | — | US | claimed |
| EP-2793954-A1 | 18F - FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS | GE Healthcare UK Limited (GB) | 2014-10-29 | — | — | EP | claimed |
| WO-2013093025-A1 | 18F - FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS | GE HEALTHCARE LIMITED (GB) | 2013-06-27 | — | — | WO | claimed |
| EP-4387974-A1 | COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS | Ascletics Bioscience Co., Ltd. (CN) | 2024-06-26 | — | — | EP | disclosed |
| CN-117813309-A | Compounds as immunomodulators for PD-L1 interactions | 歌礼生物科技（杭州）有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023019430-A1 | COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
| US-11534494-B2 | Formulation and method of synthesis | GE HEALTHCARE LIMITED (GB) | 2022-12-27 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-106458785-A | Novel formulation and method of synthesis | 通用电气健康护理有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9242924-B2 | Preparation of a 1-amino-3-hydroxy-cyclobutane-1-carboxylic acid derivative | GE HEALTHCARE LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| WO-2016001199-A1 | NOVEL FORMULATION AND METHOD OF SYNTHESIS | GE HEALTHCARE LIMITED (GB) | 2016-01-07 | — | — | WO | disclosed |
| US-20150231249-A1 | 18F-FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS | GE HEALTHCARE LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| EP-2793954-A1 | 18F - FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS | GE Healthcare UK Limited (GB) | 2014-10-29 | — | — | EP | disclosed |
| CN-103415503-A | Preparation of 1-amino-3-hydroxy-cyclobutane-1-carboxylic acid derivatives | GE HEALTHCARE LTD | 2013-11-27 | — | — | CN | disclosed |
| WO-2013093025-A1 | 18F - FLUCICLOVINE COMPOSITIONS IN CITRATE BUFFERS | GE HEALTHCARE LIMITED (GB) | 2013-06-27 | — | — | WO | disclosed |